menu search

PLRX / Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial
Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic liver disease. The trial met its primary and secondary goals, and bexotegrast was well tolerated over a 12-week treatment period in patients with primary sclerosing cholangitis (PSC) and suspected liver fibrosis, the company said in a release. Read More
Posted: Sep 26 2023, 08:09
Author Name: Market Watch
Views: 122496

PLRX News  

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

By Zacks Investment Research
September 27, 2023

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexote more_horizontal

Why Shares of Pliant Therapeutics Are Rising Tuesday

By The Motley Fool
September 26, 2023

Why Shares of Pliant Therapeutics Are Rising Tuesday

Pliant Therapeutics is a clinical-stage biotech. The company said it has enough cash to fund operations through the second half of 2026. more_horizontal

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

By Market Watch
September 26, 2023

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatme more_horizontal

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

By Seeking Alpha
August 11, 2023

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company's financials show an increase in R&D and a more_horizontal

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 9, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compar more_horizontal

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 9, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compar more_horizontal

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market

By Seeking Alpha
April 15, 2023

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market more_horizontal

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 9, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do more_horizontal


Search within

Pages Search Results: